Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Last Friday we noted that a new paper by Vickers et al. has formally recommended that PSA velocity be removed from guidelines on the use of diagnostic data to decide whether a man should have a biopsy to assess his potential risk for prostate cancer. We expressed no opinion on the article at that time
Filed under: Diagnosis, Risk | Tagged: best practice, biopsy, guideline, PSA, velocity | 2 Comments »
A new analysis of data from > 5,500 men who participated in the Prostate Cancer Prevention Trial has directly challenged the recommendation in some clinical guidelines regarding the use of PSA velocity as an indicator for immediate biopsy.
Filed under: Diagnosis, Risk | Tagged: biopsy, guidelines, PSA, velocity | Leave a Comment »
An analysis of data from the Rotterdam and Göteborg subsets of men enrolled in the European Randomized Screening for Prostate Cancer (ERSPC) study suggests that PSA velocity is of little value in the identification of men who would benefit from a second biopsy after a first, negative biopsy.
Filed under: Diagnosis, Risk | Tagged: biopsy, positive, probability, PSA, velocity | Leave a Comment »
The role of PSA kinetics (i.e., PSA doubling time and PSA velocity) in the early diagnosis of prostate cancer and in the monitoring of patients on active surveillance protocols has been controversial. We now have some more definitive data.
Filed under: Living with Prostate Cancer, Management | Tagged: active surveillance, doubling time, kinetics, PSA, PSADT, PSAV, velocity | 6 Comments »
We have commented several times on the continuing controversy between two research groups on this key topic.
Filed under: Diagnosis, Management, Risk | Tagged: doubling time, dynamics, outcome, predict, PSA, risk, velocity | 4 Comments »
Additional prostate cancer news this weekend includes the following items: The role of follow-up pathology in patients with clinical stage T1a (TURP-detected) prostate cancer The impact of the number of risk factors on the likelihood of prostate cancer-specific mortality in patients with intermediate- and high-risk disease Whether a familial history of prostate cancer affects outcomes [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: BMI, brachytherapy, cancer, factors, familyt, Gleason, hereditary, history, mortality, news update, obesity, outcome, prostate, prostatectomy, PSA, radical, risk, stage, T1a, TURP, velocity | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site